Stacey Titus • January 17, 2024
Corewell Health (formerly Spectrum Health) HCM Program – Grand Rapids, Michigan

The Hypertrophic Cardiomyopathy Program at Corewell Health (formerly Spectrum Health) in Grand Rapids, Michigan, was founded in 2013 and recognized as an HCMA Center of Excellence in 2017. 

  • The multidisciplinary team includes:
  • Dr. David Fermin – Program Director
  • Dr. Jeff Decker – Cardiovascular Imaging
  • Dr. Richard McNamara – Interventional Cardiology
  • Lori Singer – Physician Assistant
  • Jackie Sporte and Paula Droste – HCM Specialty Nurses
  • Dr. Alfred Albano and Dr. Nagib Chalfoun – Cardiac Electrophysiologists
  • Dr. Tomasz Timek – Cardiac surgeon
  • Dr. Stanley Sedore – Pediatric Cardiologist
  • Bethany Grysko – Genetic Counselor
  • Doreen McGrath and Justin Joseff – Social Workers

The Hypertrophic Cardiomyopathy Program at Corewell Health offers a “comprehensive patient-centered approach to diagnosis, education, and treatment, bringing our resources around our patients wherever possible. We facilitate family screening of HCM patients along with our pediatric cardiology clinic. Our echocardiography lab offers multiple regional locations to allow patients to remain in their community for much of their testing. Our approach has also evolved during the COVID-19 pandemic to include virtual visits with providers and our genetic counselor. Our more advanced services include cardiac MRI, heart catheterization and electrophysiology labs, as well as advanced heart failure therapies including heart transplant.”

Program Director  Dr. David Fermin says, “Our clinic cares for 1028 HCM patients and their families. Our cardiothoracic surgeon, Dr. Timek, performed 14 septal myectomy surgeries last year, contributing to an increase in our patients’ quality of life. Excitingly, we participated in groundbreaking clinical trials for Mavacamten, including EXPLORER-HCM, MAVA-LTE and VALOR-HCM, enrolling several of our patients. We continue our involvement in clinical trials of both Mavacamten and Aficamten for patients with both obstructive and nonobstructive HCM.

We have enjoyed teaming with the HCMA to enhance the lives of those with Hypertrophic Cardiomyopathy. “

The Corewell Health HCM Team recently participated in our BigHearted Warriors Unite Webinar Series. If you would like to watch this free education webinar, please visit  https://www.youtube.com/watch?v=lo7U7jZUeIg&t=106s.  

For more information on Corewell Health (formerly Spectrum Health) HCM Program in Grand Rapids, Michigan, please visit:  https://4hcm.org/corewell/


For more information on all HCMA-recognized centers of excellence, please visit  https://4hcm.org/center-of-excellence/.

HCMA Blog

Pro Publica Releases Results of FDA Investigation

By Erica Friedman • June 26, 2025
Investigative journalists Debbie Cenziper, Megan Rose, Brandon Roberts and Irena Hwang from Pro Publica and NPR have concluded a 14-month long investigation into the quality of generic drugs coming into the United States from overseas. Among the many voices that spoke up for American patients was HCMA Founder and CEO, Lisa Salberg who has felt the effects of low-quality drugs personally. Salberg believes that fixing this problem is something we can do, even in this time, when even health care is highly politicized. Read the key takeaways from ProPublica’s 14-month investigation into the FDA’s oversight of foreign drugmakers in Threat in Your Medicine Cabinet: The FDA’s Gamble on America’s Drugs .
A light blue and dark blue paintbrush stroke intersect to make a stylized

Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

By Erica Friedman • June 18, 2025
Alnylam press release on the European Commission approval of AMVUTTRA® (vutrisiran) forwild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication
Light & dark blue brush stroke that intersect create an abstract letter 'a' next to the word Alnylam

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran) for Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)

By Erica Friedman • June 17, 2025
AMVUTTRA® (vutrisiran) has been approved by the U.S. Food and Drug Administration (FDA) to treat ATTR-CM in adults.
More Posts